Question:hard
All of the following are true about fulvestrant (a selective estrogen receptor downregulator) except:
All of the following are true about fulvestrant (a selective estrogen receptor downregulator) except:
Show Hint
This SERD is a long-acting depot with a clean pure-antagonist profile.
Updated On: Jun 24, 2026
- Used for treatment of advanced breast cancer
- Also known as a pure anti-estrogen
- Is slower acting, has shorter duration of action and lower safety profile than SERMs
- Administered as a once-monthly intramuscular injection
Show Solution
The Correct Option is C
Solution and Explanation
Treat fulvestrant as the answer to the limitations of the SERM class. SERMs such as tamoxifen are mixed agonist-antagonists, retaining estrogenic effects on endometrium and clotting; fulvestrant instead binds, fully blocks and then degrades the receptor, so it is correctly called a pure anti-estrogen and lacks those agonist liabilities. Clinically it is reserved for advanced hormone-positive breast cancer, and because it is not orally usable it is formulated as a depot intramuscular shot given about once a month, giving it a long, not short, duration. The claim that it is slower acting, shorter acting and less safe than SERMs contradicts both its depot pharmacology and its cleaner agonist-free profile, so that is the untrue statement.
\[\boxed{\text{Slower acting, shorter duration, lower safety profile than SERM}}\]
Was this answer helpful?
0
